ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

PeopleandPicks.com is Zacks' Community Website
Find great stocks and great stock pickers in our online community. It's social, it's profitable and it's Free! Join the fun at PeopleandPicks.com

Quote:

Search for Ticker

Free Membership

Search:

ANDS: Anadys Pharmaceuticals Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

ANADYS PHARMACEUTICALS INC (NASD)
ANDS	2.15	N/A	(N/A%)	Vol. 0	N/A ET

Anadys Pharmaceuticals, Inc., is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company's programs focus on Toll-Like Receptor-based small molecule product candidates and direct antiviral compounds that inhibit key steps in viral proliferation. The Company has core expertise in medicinal chemistry coupled with structure-based drug design, and is developing compounds for the treatment of hepatitis C infection, hepatitis B infection and cancer.

General Information

ANADYS PHARMACT

3115 Merryfield Row San Diego, CA 92121 Phone: 858 530-3600 Fax: 858-5271540 Web: www.anadyspharma.com Email: ir@anadyspharma.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/25/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	2.15
52 Week High	8.43
52 Week Low	1.44
Beta	-0.81
20 Day Moving Average	339,940.50
Target Price Consensus	4.71

% Price Change
4 Week	-0.90
12 Week	-2.67
YTD	39.67

% Price Change Relative to S&P 500
4 Week	-1.97
12 Week	-8.24
YTD	15.59

Share Information
Shares Outstanding (millions)	37.31
Market Capitalization (millions)	81.71
Short Ratio	1.89
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.17
Current Year EPS Consensus Estimate	-0.86
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	02/25/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.44
30 Days Ago	1.25
60 Days Ago	1.67
90 Days Ago	1.80

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	34.38%
vs. Previous Quarter	0.00%

Sales Growth
vs. Previous Year	-%
vs. Previous Quarter:	-%

Price Ratios
Price/Book	4.47
Price/Cash Flow	-
Price / Sales	-

ROE
09/30/09	-144.38
06/30/09	-129.62
03/31/09	-112.75

ROA
09/30/09	-107.58
06/30/09	-102.98
03/31/09	-95.26

Current Ratio
09/30/09	2.95
06/30/09	3.80
03/31/09	3.69

Quick Ratio
09/30/09	2.95
06/30/09	3.80
03/31/09	3.69

Operating Margin
09/30/09	-
06/30/09	-
03/31/09	-

Net Margin
09/30/09	-
06/30/09	-
03/31/09	-

Pre-Tax Margin
09/30/09	-
06/30/09	-
03/31/09	-

Book Value
09/30/09	0.49
06/30/09	0.88
03/31/09	0.62

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	0.00
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	0.00
06/30/09	0.00
03/31/09	0.00


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research